Jason P Mendoza

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Respiratory Syndrome Coronavirus

Top Venues

Neurology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P Mendoza, James B Lewin, Sai L Shankar
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and therapy (2024)
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P Mendoza, James B Lewin, Sai L Shankar
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and therapy 13 (4) (2024)
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P Mendoza, James B Lewin, Sai L Shankar
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and therapy 13 (4) (2024)
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P Mendoza, James B Lewin, Sai L Shankar
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and therapy 13 (4) (2024)
Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J Tamar Kalina, Jason P Mendoza, Robin L Avila, Matthew A Tremblay
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy. Neurology and therapy (2023)
Lilyana Amezcua, Yang Mao-Draayer, Wendy S Vargas, Rebecca Farber, Sara Schaefer, Filipe Branco, Sarah M England, Nicholas Belviso, James B Lewin, Jason P Mendoza, Sai L Shankar, null null
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies. Neurology and therapy (2023)
Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J Tamar Kalina, Jason P Mendoza, Robin L Avila, Matthew A Tremblay
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy. Neurology and therapy (2023)
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M England, Sai L Shankar, Jason P Mendoza, James B Lewin
Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis. Neurology and therapy (2022)
Jacob Liseno, Brittney Lager, Catherine Miller, Sai L Shankar, Jason P Mendoza, James B Lewin
Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence. Neurology and therapy 10 (1) (2021)